000108511 001__ 108511
000108511 005__ 20231027130639.0
000108511 0247_ $$2doi$$a10.3390/jcm10163534
000108511 0248_ $$2sideral$$a124811
000108511 037__ $$aART-2021-124811
000108511 041__ $$aeng
000108511 100__ $$0(orcid)0000-0002-2338-7637$$aSánchez-Marteles, Marta$$uUniversidad de Zaragoza
000108511 245__ $$aEarly Measurement of Blood sST2 Is a Good Predictor of Death and Poor Outcomes in Patients Admitted for COVID-19 Infection
000108511 260__ $$c2021
000108511 5060_ $$aAccess copy available to the general public$$fUnrestricted
000108511 5203_ $$aAlthough several biomarkers have shown correlation to prognosis in COVID-19 patients, their clinical value is limited because of lack of specificity, suboptimal sensibility or poor dynamic behavior. We hypothesized that circulating soluble ST2 (sST2) could be associated to a worse outcome in COVID-19. In total, 152 patients admitted for confirmed COVID-19 were included in a prospective non-interventional, observational study. Blood samples were drawn at admission, 48-72 h later and at discharge. sST2 concentrations and routine blood laboratory were analyzed. Primary endpoints were admission at intensive care unit (ICU) and mortality. Median age was 57.5 years [Standard Deviation (SD: 12.8)], 60.4% males. 10% of patients (n = 15) were derived to ICU and/or died during admission. Median (IQR) sST2 serum concentration (ng/mL) rose to 53.1 (30.9) at admission, peaked at 48-72 h (79.5(64)) and returned to admission levels at discharge (44.9[36.7]). A concentration of sST2 above 58.9 ng/mL was identified patients progressing to ICU admission or death. Results remained significant after multivariable analysis. The area under the receiver operating characteristics curve (AUC) of sST2 for endpoints was 0.776 (p = 0.001). In patients admitted for COVID-19 infection, early measurement of sST2 was able to identify patients at risk of severe complications or death.
000108511 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000108511 590__ $$a4.964$$b2021
000108511 592__ $$a1.04$$b2021
000108511 594__ $$a4.4$$b2021
000108511 591__ $$aMEDICINE, GENERAL & INTERNAL$$b55 / 172 = 0.32$$c2021$$dQ2$$eT1
000108511 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000108511 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000108511 700__ $$0(orcid)0000-0002-4769-7154$$aRubio-Gracia, Jorge$$uUniversidad de Zaragoza
000108511 700__ $$aPeña-Fresneda, Natacha
000108511 700__ $$aGarcés-Horna, Vanessa$$uUniversidad de Zaragoza
000108511 700__ $$aGracia-Tello, Borja
000108511 700__ $$0(orcid)0000-0003-3043-147X$$aMartínez-Lostao, Luis$$uUniversidad de Zaragoza
000108511 700__ $$aCrespo-Aznárez, Silvia
000108511 700__ $$0(orcid)0000-0003-2361-9941$$aPérez-Calvo, Juan Ignacio$$uUniversidad de Zaragoza
000108511 700__ $$0(orcid)0000-0002-6043-4869$$aGiménez-López, Ignacio$$uUniversidad de Zaragoza
000108511 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000108511 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000108511 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000108511 773__ $$g10, 16 (2021), 3534 [14 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000108511 8564_ $$s1018858$$uhttps://zaguan.unizar.es/record/108511/files/texto_completo.pdf$$yVersión publicada
000108511 8564_ $$s2743989$$uhttps://zaguan.unizar.es/record/108511/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000108511 909CO $$ooai:zaguan.unizar.es:108511$$particulos$$pdriver
000108511 951__ $$a2023-10-27-12:53:42
000108511 980__ $$aARTICLE